Molecular Diagnostics: Page 3

Study uncovers role of genetic variants in blood cancer development

By Matt Limb

Scientists have used large scale data analysis to investigate why only some people with a common mutation go on to develop rare blood cancer.

January 23, 2024

First FDA-approved CRISPR-based gene therapy cleared for 2nd indication

By LabPulse.com staff writers

A month after the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, the agency has given it a second U.S. regulatory approval ahead of schedule.

January 17, 2024

Weill Cornell study may support new prognostic test for prostate tumor spread

By LabPulse.com staff writers

Scientists working in the department of pathology and laboratory medicine at Weill Cornell Medicine have found that certain noncancerous cells may be useful for assessing prostate tumors and their potential to spread.

January 16, 2024

Genevant Sciences forges $114M deal with Tome Biosciences on liver disease gene therapy

By LabPulse.com staff writers

Biotech firm Genevant Sciences will collaborate with biotech startup Tome Biosciences on an in vivo gene editing treatment for a rare liver disorder.

January 16, 2024

IGI, Danaher launch CRISPR gene therapy research center

By LabPulse.com staff writers

Danaher and the Innovative Genomics Institute (IGI) have launched a collaborative research center aimed at developing CRISPR-based gene therapies for a wide array of diseases.

January 12, 2024

Gene therapy, companion diagnostic hit milestones for hemophilia A

By Liz Carey

Six months after the FDA approved a one-time gene therapy for severe hemophilia A reportedly priced around $2.5 million per patient, the Center for Inherited Blood Disorders, a 340B treatment center in California, has announced the drug's first infusion.

January 11, 2024

Tome Biosciences acquires Replace Therapeutics in $65M deal

By LabPulse.com staff writers

Less than a month after Tome Biosciences emerged with $213 million in funding, the gene editing company will acquire Replace Therapeutics for $65 million in upfront and near-term milestones, with a total deal value of up to $185 million.

January 5, 2024

Thermo Fisher goes big with new pangenome array

By LabPulse.com staff writers

Thermo Fisher Scientific announced the launch of a new human genomics research tool that complements the recent development of the pangenome.

January 5, 2024

Biotech startup Moonwalk Biosciences launches with $57M in financing

By LabPulse.com staff writers

New biotechnology startup Moonwalk Biosciences has launched with the completion of $57 million in seed and series A financing to advance its epigenetic profiling and engineering technology platform and therapeutics for a range of conditions.

January 4, 2024

Heated legal battles continue in cell-free DNA testing market

By Liz Carey

Clinical genetic testing manufacturer Natera announced another victory in its fight to stop other companies from capitalizing on cell-free DNA (cfDNA) testing that appears to infringe on its patents. More genetic testing patent disputes are pending.

January 2, 2024

Thermo Fisher launches new instrument, kit for respiratory testing

By LabPulse.com staff writers

Thermo Fisher Scientific has launched a nucleic acid purification instrument and kit for automated viral and bacterial respiratory testing.

December 11, 2023

King's College London, bit.bio collaboration launched to build multicell brain models

By Matt Limb

A collaboration has been launched in the U.K. to build multicell models of the human brain deemed vital to develop novel therapies for neuronal and psychiatric disorders.

December 5, 2023

Previous Page

Page 3 of 193

Next Page